# US 2026/0217687 A1 · Mlh1 selective (series 1b) compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0217687 A1
- Document ID: US20260217687A1
- Status: Published application
- Kind: A1
- Application number: 19/148,966
- Filed: 2024-01-19
- Published: 2026-07-30
- Earliest claimed: 2023-01-20
- Assignees: NeoPhore Limited
- Applicants: NeoPhore Limited
- Inventors: Julian Blagg; Martin Drysdale; Paul Winship; Stuart Rankin; Alastair Rae; Jacob Bestwick
- Web page: https://patentgrep.com/patent/US20260217687A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 217/06: with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of Formula (I) that target MLH1, a component of the DNA Mismatch Repair (MMR) process: wherein R2, R3, R4, R5, Y1, Y2, A1, A2, A3, and A4 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 activity is implicated (e.g. Triplet Repeat Disorders).

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, having the structural Formula (I) shown below:
wherein
R2 is hydrogen or fluoro;
R3 is selected from halo, cyano, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, (1-2C)alkoxy, (1-2C)haloalkoxy;
R4 is selected from hydrogen, halo or cyano;
or R3 and R4 are linked to form:
a fused 5- or 6-membered carbocyclic or heterocyclic ring;
a fused phenyl ring; or
a 5- or 6-membered heteroaryl ring;
each of which is optionally further substituted by halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1-2C)haloalkoxy;
R5 is R6 or —OR6;
wherein R6 is (1-6C)alkyl, (3-8C)cycloalkyl, a 4- to 7-membered heterocyclyl ring comprising one heteroatom selected from N, O or S, phenyl, or a 5- or 6-membered heteroaryl; each of which is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy;
or a group having a structure according to formula (A) shown below:
wherein
R7 is hydrogen or (1-3C)alkyl;
n is 1 or 2;
R8 is (3-8C)cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is optionally substituted with one or more R9; where each R9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy;
Y1 is a bond, —CH2—, —CH2—CH2— or —C(═O)—;
Y2 is —CH2—, —C(═O)—, —CHRy2a—, —CH2—CH2—, —CH2—CHRy2b—, or —CHRy2a—CH2—; where Ry2a is selected from halo, cyano, methyl, methoxy, CF3, —OCF3 or hydroxymethyl, and Ry2b is selected from halo, cyano, hydroxy, methyl, methoxy, CF3, —OCF3 or hydroxymethyl, provided that when Y1 is a bond, Y2 is —CH2—CH2—, —CH2—CHRy2b—, or —CHRy2a—CH2—;
A1 is selected from N, CH or CR11;
A2 is selected from N, CH or CR12;
A3 is selected from N, CH or CR13;
A4 is selected from N, CH or CR14;
with the proviso that only one or two of A1, A2, A3 or A4 can be N;
R11 is cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy;
or R11 is —(CHRz)a—Z11,
wherein:
Rz is hydrogen or methyl;
a is 0 or 1; and
Z11 is —OR15, R15a, —NR16R17, —C(O)NR16R17 or —NR18C(O)R19;
wherein
R15 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRy)b-(3-7C)cycloalkyl, —(CHRy)b-phenyl, —(CHRy)b-[4 to 8-membered heterocyclyl] or —(CHRy)b-[5 or 6 membered heteroaryl], wherein Ry is hydrogen or methyl and b is 0, 1 or 2;
R15a is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRy)b-(3-7C)cycloalkyl, —(CHRy)b-phenyl, —(CHRy)b-[4 to 8-membered heterocyclyl] or —(CHRy)b-[5 or 6 membered heteroaryl], wherein Ry is hydrogen or methyl and b is 0, 1 or 2;
R16 and R17 are each independently selected from hydrogen, (1-6C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRw)c-(3-7C)cycloalkyl, —(CHRw)c-phenyl, —(CHRw)c-[4 to 8-membered heterocyclyl] or —(CHRw)c-[5 or 6 membered heteroaryl], wherein Ry is hydrogen or methyl and c is 0, 1 or 2;
or R16 and R17 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
R18 is hydrogen or (1-2C)alkyl;
R19 is (1-6C)alkyl, (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRx)d-(3-7C)cycloalkyl, —(CHRx)d-phenyl, —(CHRx)d-[4 to 8-membered heterocyclyl] or —(CHRx)d-[5 or 6 membered heteroaryl];
wherein R is hydrogen or methyl and d is 0 or 1;
wherein each of R11, R15, R15a, R16, R17, R18 or R19, or any ring formed when R16 and R17 are linked, is optionally substituted with one or more Ra;
R12 is selected from one of the following options:
(i) when R11 is a group —(CHRz)a—Z11 then R12 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
(ii) when R11 is not a group —(CHRz)a—Z11 then R12 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
R12 is —(CHRv)d—Z12,
wherein:
Rv is hydrogen or methyl;
d is 0 or 1; and
Z12 is —OR20, R20a, —NR21R22, —C(O)NR21R22 or —NR23C(O)R24;
wherein R20 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRu)e-(3-7C)cycloalkyl, —(CHRu)e-phenyl, —(CHRu)e-[4 to 8-membered heterocyclyl] or —(CHRu)e-[5 or 6 membered heteroaryl], wherein Ru is hydrogen or methyl and e is 0, 1, 2 or 3;
R20a is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRu)e-(3-7C)cycloalkyl, (CHRu)e-phenyl, —(CHRu)e-[4 to 8-membered heterocyclyl] or —(CHRu)e-[5 or 6 membered heteroaryl], wherein Ru is hydrogen or methyl and e is 0, 1, 2 or 3;
R21 and R22 are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRq)f-(3-7C)cycloalkyl, —(CHRq)f-phenyl, —(CHRq)f-[4 to 8-membered heterocyclyl] or —(CHRq)f-[5 or 6 membered heteroaryl], wherein Rq is hydrogen or methyl and f is 0 or 1;
or R21 and R22 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
R23 is hydrogen or (1-2C)alkyl;
R24 is (1-6C)alkyl, (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRp)g-(3-7C)cycloalkyl, —(CHRp)g-phenyl, —(CHRp)g-[4 to 8-membered heterocyclyl] or —(CHRp)g-[5 or 6 membered heteroaryl], wherein Rp is hydrogen or methyl and g is 0 or 1;
wherein each of R12, R20, R20a, R21, R22, R23 or R24, or any ring formed when R21 and R22 are linked, is optionally substituted with one or more Ra;
R13 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted by one or more halo or (1-2C)alkoxy, or
R13 is —(CHRo)h—Z13,
wherein:
Ro is hydrogen or methyl;
h is 0 or 1; and
Z13 is —OR25, R25a, —NR26R27, —C(O)NR26R27 or —NR28C(O)R29;
wherein R25 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRn)i-(3-7C)cycloalkyl, —(CHRn)i-phenyl, —(CHRn)i—[4 to 8-membered heterocyclyl] or —(CHRn)i-[5 or 6 membered heteroaryl], wherein Rn is hydrogen or methyl and i is 0, 1 or 2;
R25a is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRn)i-(3-7C)cycloalkyl, —(CHRn)i-phenyl, —(CHRn)i-[4 to 8-membered heterocyclyl] or —(CHRn)i—[5 or 6 membered heteroaryl], wherein Rn and i are as defined above;
R26 and R27 are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, phenyl a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRm)j-(3-7C)cycloalkyl, —(CHRm)j-phenyl, —(CHRm)j-[4 to 8-membered heterocyclyl] or —(CHRm)j-[5 or 6 membered heteroaryl], wherein Rm is hydrogen or methyl and j is 0 or 1;
or R26 and R27 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
R28 is hydrogen or (1-2C)alkyl;
R29 is (1-6C)alkyl, (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRl)k-(3-7C)cycloalkyl, —(CHRl)k-phenyl, —(CHRl)k-[4 to 8-membered heterocyclyl] or —(CHRl)k-[5 or 6 membered heteroaryl], wherein Rl is hydrogen or methyl and k is 0 or 1;
wherein each of R13, R25, R25a, R26, R27, R28 or R29 or any ring formed when R26 and R27 are linked, is optionally substituted with one or more Ra;
R14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
R14 is —(CHRk)m—Z14,
wherein Rk is hydrogen or methyl;
wherein m is 0 or 1; and
Z14 is —OR30, R30a, —NR31R32, —C(O)NR31R32 or —NR33C(O)R34;
wherein R30 is (1-4C)alkyl, (3-7C)cycloalkyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRj)o-(3-7C)cycloalkyl, —(CHRj)o-[4 to 8-membered heterocyclyl] or —(CHRj)o-[5 or 6 membered heteroaryl], wherein R; is hydrogen or methyl and o is 0 or 1;
R30a is (1-4C)alkyl, (3-7C)cycloalkyl, 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRj)o-(3-7C)cycloalkyl, —(CHRj)o-[4 to 8-membered heterocyclyl] or —(CHRj)o-[5 or 6 membered heteroaryl], wherein Rj is hydrogen or methyl and o is 0 or 1;
R31 and R32 are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRj)p-(3-7C)cycloalkyl, —(CHRj)p-[4 to 8-membered heterocyclyl] or —(CHRj)p-[5 or 6 membered heteroaryl], wherein R; is hydrogen or methyl and p is 0 or 1
or R31 and R32 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
R33 is hydrogen or (1-2C)alkyl;
R34 is (1-6C)alkyl, (2-6C)alkynyl, (3-7C)cycloalkyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRh)q-(3-7C)cycloalkyl, —(CHRh)q-[4 to 8-membered heterocyclyl] or —(CHRh)q-[5 or 6 membered heteroaryl], wherein Rh is hydrogen or methyl and q is 0 or 1;
wherein R14, R30, R30a, R31, R32, R33 or R34, or any ring formed when R31 and R32 are linked, is optionally substituted with one or more Ra;
and wherein each Ra is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, (1-4C)alkyl, or a group
wherein:
L1 is absent or (1-2C)alkylene;
X1 is absent or is selected from the group consisting of —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R14)—, —N(R14)—C(O)—, —NR14—, —N(R14)—C(O)—NR14—, —SO2N(R14)—, or —N(R14)SO2—, where R14 is hydrogen or (1-2C)alkyl;
Q1 is selected from the group consisting of hydrogen, (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, or (3-6C)cycloalkyl;
wherein when Q1 is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, or (3-6C)cycloalkyl, Q1 is optionally substituted with one or more Qa, where each Qa is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy;
and wherein one of R12 or R13 is optionally a group:
wherein L is a linker;
Lx is a linker;
X is a functional group; and
Q is a detection moiety.

### Claim 2 (depends on 1)

A compound according to claim 1 or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is hydrogen.

### Claim 3 (depends on 1, 2)

A compound according to claim 1 or claim 2, wherein the compound is a compound having one of the formulae (I-I) to (I-XLV) shown below, or pharmaceutically acceptable salt thereof:
wherein R3, R4, R5, Y1, Y2, A1, A2, A3 and A4 are each as defined in claim 1.

### Claim 4 (depends on 1, 2, 3)

A compound according to any one of claims 1 to 3, or pharmaceutically acceptable salt thereof, wherein:
R4 is hydrogen and R3 is selected from halo, cyano, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, (1-2C)alkoxy, (1-2C)haloalkoxy;
or R3 and R4 are linked to form a fused 5- or 6-membered carbocyclic or heterocyclic ring, which is optionally further substituted by halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1-2C)haloalkoxy.

### Claim 5 (depends on 1, 2, 3, 4)

A compound according to any one of claims 1 to 4, or pharmaceutically acceptable salt thereof, wherein:
R4 is hydrogen and R3 is selected from halo, cyano, (1-2C)alkyl, (1-2C)fluoroalkyl, (1-2C)alkoxy, (1-2C)fluoroalkoxy;
or R3 and R4 are linked to form a fused 5- or 6-membered carbocyclic or heterocyclic ring, which is optionally further substituted by halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)fluoroalkyl, (1-2C)alkoxy or (1-2C)fluoroalkoxy.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A compound according to any one of claims 1 to 5, or pharmaceutically acceptable salt thereof, wherein:
R4 is hydrogen and R3 is selected from halo, cyano, methyl, fluoromethyl, di-fluoromethyl, trifluoromethyl, methoxy, di-fluoromethoxy or trifluoromethoxy;
or R3 and R4 are linked to form a fused 5- or 6-membered carbocyclic or heterocyclic ring, which is optionally further substituted by halo, cyano, methyl, fluoromethyl, di-fluoromethyl, trifluoromethyl, methoxy, di-fluoromethoxy or trifluoromethoxy.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A compound according to any one of claims 1 to 6, or pharmaceutically acceptable salt thereof, wherein:
R4 is hydrogen and R3 is selected from halo, cyano, methyl, di-fluoromethyl, trifluoromethyl, or methoxy;
or R3 and R4 are linked to form a fused 5- or 6-membered carbocyclic or heterocyclic ring, which is optionally further substituted by halo, cyano, methyl, di-fluoromethyl, trifluoromethyl or methoxy.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A compound according to any one of claims 1 to 7, or pharmaceutically acceptable salt thereof, wherein:
R4 is hydrogen and R3 is selected from halo, cyano, methyl, di-fluoromethyl, trifluoromethyl, or methoxy;
or R3 and R4 are linked to form a fused 5- or 6-membered carbocyclic or heterocyclic ring.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A compound according to any one of claims 1 to 8, or pharmaceutically acceptable salt thereof, wherein:
R4 is hydrogen and R3 is selected from halo, cyano, methyl, di-fluoromethyl, trifluoromethyl, or methoxy;
or R3 and R4 are linked to form a fused 5- or 6-membered cycloalkyl ring.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A compound according to any one of claims 1 to 9, or pharmaceutically acceptable salt thereof, wherein R5 is —OR6.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound according to any one of claims 1 to 10, or pharmaceutically acceptable salt thereof, wherein R5 is —OR6, wherein:
(i) R6 is (1-6C)alkyl, (3-6C)cycloalkyl, or a 4- to 6-membered heterocyclyl ring comprising one heteroatom selected from N, O or S,
or a group having a structure according to formula (A) shown below:
wherein
R7 is hydrogen or (1-3C)alkyl;
n is 1 or 2;
R8 is (3-8C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, or 9- or 10-membered fused bicyclic heteroaryl, each of which is optionally substituted with one or more R9; where each R9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy, and wherein any 4- to 6-membered heterocyclyl optionally comprises 1 or 2 additional bridging atoms;
(ii) R6 is (1-4C)alkyl or a group having a structure according to formula (A) shown below:
wherein
R7 is hydrogen or (1-2C)alkyl;
n is 1 or 2;
R8 is (3-6C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, 5- or 6-membered heteroaryl, or 9- or 10-membered fused bicyclic heteroaryl, each of which is optionally substituted with one or more R9; where each R9 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy, and wherein any 4- to 6-membered heterocyclyl optionally comprises 1 additional bridging atom;
(iii) R6 is (1-3C)alkyl or a group having a structure according to formula (A) shown below:
wherein
R7 is hydrogen or methyl;
n is 1;
R8 is (3-6C)cycloalkyl, phenyl, 6-membered heterocyclyl, 6-membered heteroaryl, or 9- or 10-membered fused bicyclic heteroaryl, each of which is optionally substituted with one or more R9; where each R9 is independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, or trifluoromethoxy;
(iv) R6 is methyl, ethyl or a group having a structure according to formula (A) shown below:
wherein
R7 is hydrogen or methyl;
n is 1;
R8 is cyclopropyl, cyclohexyl, phenyl, 6-membered heterocyclyl, pyridyl, benzimidazole or quinoline, each of which is optionally substituted with one or more R9; where each R9 is independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; or
(v) R6 is methyl or a group having a structure according to formula (A) shown below:
wherein
R7 is hydrogen;
n is 1;
R8 is cyclopropyl or phenyl.
(vi) R6 is a group having a structure according to formula (A) shown below:
wherein
R7 is hydrogen;
n is 1;
R8 is phenyl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound according to any one of claims 1 to 11, or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
(i) Y1 is a bond, —CH2— or —CH2—CH2—; and/or
(ii) Y2 is —CH2—, —CHRy2a—, —CH2—CH2—, —CH2—CHRy2b—, or —CHRy2a—CH2—; where Ry2a is selected from halo, methyl or hydroxymethyl, and Ry2b is selected from halo, cyano, hydroxy, methyl, methoxy, CF3, —OCF3 or hydroxymethyl, provided that when Y1 is a bond, Y2 is —CH2—CH2—, —CH2—CHRy2b—, or —CHRy2a—CH2—; or
(iii) Y2 is —CH2— or —CH2—CH2—, provided that when Y1 is a bond, Y2 is —CH2—CH2—.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A compound according to any one of claims 1 to 12, or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein A1, A2, A3 or A4 are selected from one of the following options:
(i) A1 is selected from N, CH or OR11;
A2 is selected from N, CH or CR12;
A3 is selected from N, CH or CR13;
A4 is selected from N, CH or CR14;
with the proviso that only one of A1, A2, A3 or A4 can be N.
(ii) A1 is selected from CH or OR11;
A2 is selected from N, CH or CR12;
A3 is selected from N, CH or CR13;
A4 is selected from N, CH or CR14;
with the proviso that only one of A2, A3 or A4 can be N;
(iii) A1 is CR11;
A2 is selected from N, CH or CR12;
A3 is selected from N, CH or CR13;
A4 is selected from N, CH or CR14;
with the proviso that only one of A2, A3 or A4 can be N;
(iv) A1 is OR11;
A2 is selected from N or CH;
A3 is selected from N, CH or CR13;
A4 is selected from N or CH;
with the proviso that only one of A2, A3 or A4 can be N;
(v) A1 is CR11;
A2 is CH;
A3 is CH or CR13;
A4 is CH;
(vi) A1 is CR11;
A2 is CH;
A3 is CH;
A4 is CH;
(vii) A1 is CH;
A2 is CR12;
A3 is CH;
A4 is CH; or
(viii) A1 is CH;
A2 is CH;
A3 is CR13;
A4 is CH.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound according to any one of claims 1 to 11, or pharmaceutically acceptable salt thereof, wherein A1, A2, A3 or A4 are selected from one of the following options:
(i) A1 is CH or CR11;
A2 is CH;
A3 is CH or CR13;
A4 is CH;
(ii) A1 is CR11;
A2 is CH;
A3 is CH;
A4 is CH;
(iii) A1 is CH;
A2 is CR12;
A3 is CH;
A4 is CH; or
(iv) A1 is CH;
A2 is CH;
A3 is CR13;
A4 is CH.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound according to any one of claims 1 to 11, or pharmaceutically acceptable salt thereof, wherein
A1 is CH or CR11;
A2 is CH;
A3 is CH or CR13; and
A4 is CH.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A compound according to any one of claims 1 to 15, or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
(A) R11 is cyano, halo or (1-2C)alkyl optionally substituted by one or more Ra;
or —(CHRz)a—Z11,
wherein Rz is hydrogen or methyl;
wherein a is 0 or 1; and
Z11 is —OR15, —NR16R17, —C(O)NR16R17 or —NR18C(O)R19;
wherein R15 is (1-4C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRy)b-(3-6C)cycloalkyl, —(CHRy)b-phenyl, —(CHRy)b-[4 to 6-membered heterocyclyl] or —(CHRy)b-[5 or 6 membered heteroaryl], wherein Ry is hydrogen or methyl and b is 0 or 1;
R16 and R17 are each independently selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRw)c-(3-6C)cycloalkyl, —(CHRw)c-phenyl, —(CHRw)c-[4 to 6-membered heterocyclyl] or —(CHRw)c-[5 or 6 membered heteroaryl], wherein Rw is hydrogen or methyl and c is 0 or 1
or R16 and R17 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;
R18 is hydrogen or (1-2C)alkyl;
R19 is (1-6C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRx)d-(3-6C)cycloalkyl, —(CHRx)d-phenyl, —(CHRx)d-[4 to 6-membered heterocyclyl] or —(CHRx)d-[5 or 6 membered heteroaryl];
wherein Rx is hydrogen or methyl and d is 0 or 1;
wherein each of R15, R16, R17, R18 or R19, or any ring formed when R16 and R17 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1;
(B) R11 is cyano or —(CHRz)a—Z11,
wherein Rz is hydrogen or methyl;
wherein a is 0 or 1; and
Z11 is —OR15, —NR16R17 or —NR18C(O)R19;
wherein R15 is (1-4C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRy)b-(3-6C)cycloalkyl, —(CHRy)b-phenyl, —(CHRy)b-[4 to 6-membered heterocyclyl] or —(CHRy)b-[5 or 6 membered heteroaryl], wherein Ry is hydrogen or methyl and b is 0 or 1;
R16 and R17 are each independently selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRw)c-(3-6C)cycloalkyl, —(CHRw)c-phenyl, —(CHRw)c-[4 to 6-membered heterocyclyl] or —(CHRw)c-[5 or 6 membered heteroaryl], wherein Rw is hydrogen or methyl and c is 0 or 1
or R16 and R17 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;
R18 is hydrogen or (1-2C)alkyl;
R19 is (1-6C)alkyl, (3-6C)cycloalkyl, phenyl, a carbon-linked 4 to 6-membered heterocyclyl, a 5 or 6 membered heteroaryl, or —(CHRx)d-(3-6C)cycloalkyl;
wherein Rx is hydrogen or methyl and d is 0 or 1;
wherein each of R15, R16, R17, R18 or R19, or any ring formed when R16 and R17 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1;
(C) R11 is —(CHRz)a—Z11,
wherein Rz is hydrogen;
wherein a is 0 or 1; and
Z11 is: —OR15, wherein R15 is (1-4C)alkyl; or
—NHR17, wherein R17 is selected from:
(i) a group of the formula (A), (B), (C) or (D):
wherein
W1 is selected from ORw1a or NRw1aRw1b, where Rw1a and Rw1b are each independently selected from hydrogen or (1-2C)alkyl;
RW1C, RW1D and RW1E are selected from hydrogen or methyl, or RW1C and RW1D or RW1D and RW1E are linked such that, together with the carbon atoms to which they are attached, they form a (4-6C)cycloalkyl ring or 5 or 6 membered heterocyclyl ring, each of which is optionally substituted by one or more Ra;
W2 is selected from O, NRw2, S or S(O)2 where Rw2 is selected from hydrogen, (1-4C)alkyl or (2-4C)alkanoyl;
and each of formulae (B), (C) and (D) is optionally substituted by one or more Ra;
wherein Ra is as defined in claim 1;
(ii) a bridged version of formulae (C) and (D) above, optionally selected from one of formulae (E) to (J) below:
wherein Y4 is selected from —CH2—, —CH2CH2—,
and each of formulae (E), (F), (G), (H) and (J) is optionally substituted by one or more Ra;
wherein Ra is as defined in claim 1;
(iii) a group of the formula (K), (L) or (M) below:
wherein:
RW3 is selected from hydrogen or (1-2C)alkyl;
W3, W4 and W5 are selected from N or CRw4 where Rw4 is hydrogen, halo, (1-2C)alkyl or (1-2C)alkoxy;
one of W6 and W7 is N and the other is CRw5 and W8 is N or CRw5, where Rw5 is hydrogen, halo, (1-2C)alkyl or (1-2C)alkoxy;
W9, W10, W11 and W12 are selected from N or CRw6 where Rw6 is hydrogen, halo, (1-2C)alkyl or (1-2C)alkoxy; with the proviso that only one or two of W9, W10, W11 and W12 are N;
(D) R11 is —(CHRz)a—Z11,
wherein Rz is hydrogen;
wherein a is 0 or 1; and
Z11 is: —OR15, wherein R15 is (1-3C)alkyl; or
—NHR11, wherein R17 is selected from:
(i) a group of the formula (A), (B), (C) or (D):
wherein
W1 is selected from ORw1a or NRw1aRw1b, where Rw1a and Rw1b are each independently selected from hydrogen or (1-2C)alkyl;
RW1C, RW1D and RW1E are selected from hydrogen, or RW1C and RW1D or RW1D and RW1E are linked such that, together with the carbon atoms to which they are attached, they form a (4-6C)cycloalkyl ring or 5 or 6 membered heterocyclyl ring, each of which is optionally substituted by one or more Ra;
W2 is selected from 0, NRw2 or S(O)2 where Rw2 is selected from hydrogen, (1-2C)alkyl or (2C)alkanoyl;
and each of formulae (B), (C) and (D) is optionally substituted by one or more Ra;
wherein Ra is as defined in claim 1;
(ii) a bridged version of formulae (C) and (D) above, optionally selected from one of formulae (E) to (J) below:
wherein Y4 is selected from —CH2—, —CH2CH2—,
and each of formulae (E), (F), (G), (H) and (J) is optionally substituted by one or more Ra;
wherein Ra is as defined in claim 1;
(iii) a group of the formula (K), (L) or (M) below:
wherein:
RW3 is selected from hydrogen or (1-2C)alkyl;
W3, W4 and W5 are selected from N or CH;
one of W6 and W7 is N and the other is CH and W8 is N or CH;
W9, W10, W11 and W12 are selected from N or CRw6 where Rw6 is hydrogen, halo, (1-2C)alkyl or (1-2C)alkoxy; with the proviso that only one of W9, W10, W11 and W12 is N.
(E) R11 is —(CHRz)a—Z11,
wherein Rz is hydrogen;
wherein a is 0 or 1; and
Z11 is: —OR15, wherein R15 is (1-2C)alkyl; or
—NHR17, wherein R17 is a group of the formula (A), (B), (C) or (D):
wherein
W1 is selected from ORw1a or NRw1aRw1b, where Rw1a and Rw1b are each independently selected from hydrogen or (1-2C)alkyl;
RW1C, RW1D and RW1E are selected from hydrogen, or RW1C and RW1D or RW1D and RW1E are linked such that, together with the carbon atoms to which they are attached, they form a (4-6C)cycloalkyl ring or 5 or 6 membered heterocyclyl ring, each of which is optionally substituted by one or more Ra;
W2 is selected from O, NRw2 or S(O)2 where Rw2 is selected from hydrogen, (1-2C)alkyl or (2C)alkanoyl;
and each of formulae (B), (C) and (D) is optionally substituted by one or more Ra;
wherein Ra is as defined in claim 1; or
a group of the formula (K), (L) or (M) below:
wherein:
RW3 is selected from hydrogen or methyl;
W3, W4 and W5 are selected from N or CH;
one of W6 and W7 is N and the other is CH and W8 is N or CH;
W9, W10, W11 and W12 are selected from N or CRw6 where Rw6 is hydrogen, halo, (1-2C)alkyl or (1-2C)alkoxy; with the proviso that only one of W9, W10, W11 and W12 is N; or
(F) R11 is Z11,
Z11 is: —OR15, wherein R15 is (1-2C)alkyl; or
—NHR17, wherein R17 is selected from:
a group of the formula (A), (B), (C), (D) or (M):
wherein
W1 is selected from ORw1a or NRw1aRw1b, where Rw1a and Rw1b are each independently selected from hydrogen or (1-2C)alkyl;
RW1C, RW1D and RW1E are selected from hydrogen, or RW1C and RW1D or RW1D and RW1E are linked such that, together with the carbon atoms to which they are attached, they form a (4-6C)cycloalkyl ring or 5 or 6 membered heterocyclyl ring, each of which is optionally substituted by one or more Ra;
W2 is selected from O, NRw2 or S(O)2 where Rw2 is selected from hydrogen, (1-2C)alkyl or (2C)alkanoyl;
and each of formulae (B), (C) and (D) is optionally substituted by one or more Ra;
wherein Ra is as defined in claim 1;
W9, W10, W11 and W12 are selected from N or CRw6 where Rw6 is hydrogen, halo, (1-2C)alkyl or (1-2C)alkoxy; with the proviso that only one of W9, W10, W11 and W12 is N;
(G) R11 is Z11,
Z11 is: —OR15, wherein R15 is methyl; or
—NHR17, wherein R17 is selected from:
a group of the formula (B), (C), (D) or (M):
wherein
W2 is selected from O, NRw2 or S(O)2 where Rw2 is selected from hydrogen, (1-2C)alkyl or (2C)alkanoyl;
and each of formulae (B), (C) and (D) is optionally substituted by oxo (═O);
W9, W10, W11 and W12 are selected from N or CH; with the proviso that only one of W9, W10, W11 and W12 is N.
(H) R11 is Z11,
Z11 is: —OR15, wherein R15 is methyl; or
—NHR17, wherein R17 is selected from:
a group of the formula (B), (C) or (D):
wherein
W2 is selected from O, NRw2 or S(O)2 where Rw2 is selected from hydrogen, (1-2C)alkyl or (2C)alkanoyl;
and each of formulae (B), (C) and (D) is optionally substituted by oxo (═O).
(I) R11 is Z11,
Z11 is —NHR17, wherein R17 is selected from:
a group of the formula (B), (C) or (D):
wherein
W2 is O;
and each of formulae (B), (C) and (D) is optionally substituted by oxo (═O);
(J) R11 is Z11,
Z11 is —NHR17, wherein R17 is selected from:
a group of the formula (B):
wherein
W2 is O.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A compound according to any one of claims 1 to 16, or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
(A) R12 is selected from one of the following options:
(i) when R11 is a group —(CHRz)a—Z11 then R12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
(ii) when R11 is not a group —(CHRz)a—Z11 then R12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
R12 is —(CHRv)d—Z12
wherein Rv is hydrogen or methyl;
wherein d is 0 or 1; and
Z12 is —OR20, —NR21R22, —C(O)NR21R22 or —NR21C(O)R24;
wherein R20 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRu)e-(3-7C)cycloalkyl, —(CHRu)e-phenyl, —(CHRu)e-[4 to 8-membered heterocyclyl] or —(CHRu)e-[5 or 6 membered heteroaryl], wherein Ru is hydrogen and e is 0, 1 or 2;
R21 and R22 are each independently selected from hydrogen, (1-6C)alkyl, (3-6C)alkanoyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRq)f-(3-7C)cycloalkyl, —(CHRq)f-phenyl, —(CHRq)f-[4 to 8-membered heterocyclyl] or —(CHRq)f-[5 or 6 membered heteroaryl], wherein Rq is hydrogen or methyl and f is 0 or 1;
or R21 and R22 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
R23 is hydrogen or methyl;
R24 is (1-6C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRp)g-(3-7C)cycloalkyl, —(CHRp)g-phenyl, —(CHRp)g-[4 to 8-membered heterocyclyl] or —(CHRp)g-[5 or 6 membered heteroaryl], wherein Rp is hydrogen or methyl and g is 0 or 1;
wherein each of R20, R21, R22, R23 or R24, or any ring formed when R21 and R22 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1;
(B) R12 is selected from one of the following options:
(i) when R11 is a group —(CHRz)a—Z11 then R12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
(ii) when R11 is not a group —(CHRz)a—Z11 then R12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
R12 is —(CHRv)d—Z12
wherein R11 is hydrogen;
wherein d is 0 or 1; and
Z12 is —OR20, —NR21R22 or —C(O)NR21R22;
wherein R20 is (1-4C)alkyl;
R21 and R22 are each independently selected from hydrogen, (1-6C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, or a 5 or 6 membered heteroaryl;
or R21 and R22 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
wherein each of R20, R21 or R22, or any ring formed when R21 and R22 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1;
(C) R12 is selected from one of the following options:
(i) when R11 is a group —(CHRz)a—Z11 then R12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
(ii) when R11 is not a group —(CHRz)a—Z11 then R12 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy;
(D) R12 is selected from fluoro, chloro, (1-2C)alkyl or (1-2C)alkoxy; or
(E) R12 is fluoro, chloro or (1-2C)alkoxy.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A compound according to any one of claims 1 to 17, or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
(A) R13 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted by one or more halo or (1-2C)alkoxy, or
R13 is —(CHRo)h—Z13,
wherein R0 is hydrogen or methyl;
wherein h is 0 or 1; and
Z13 is —OR25, R25a, —NR26R27, —C(O)NR26R27 or —NR28C(O)R29;
wherein R25 is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRn)i-(3-7C)cycloalkyl, —(CHRn)i-phenyl, —(CHRn)i-[4 to 8-membered heterocyclyl] or —(CHRn)i-[5 or 6 membered heteroaryl], wherein Rn is hydrogen or methyl and i is 0 or 1;
R25a is (1-4C)alkyl, (3-7C)cycloalkyl, phenyl, 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRn)i-(3-7C)cycloalkyl, —(CHRn)i-phenyl, —(CHRn)i-[4 to 8-membered heterocyclyl] or —(CHRn)i-[5 or 6 membered heteroaryl], wherein Rn and i are as defined above;
R26 and R27 are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRm)j-(3-7C)cycloalkyl, —(CHRm)j-phenyl, —(CHRm)j-[4 to 8-membered heterocyclyl] or —(CHRm)j-[5 or 6 membered heteroaryl], wherein Rm is hydrogen or methyl and j is 0 or 1;
or R26 and R27 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
R28 is hydrogen or methyl;
R29 is (1-6C)alkyl, (3-7C)cycloalkyl, phenyl, a carbon-linked 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRl)k-(3-7C)cycloalkyl, —(CHRl)k-phenyl, —(CHRl)k-[4 to 8-membered heterocyclyl] or —(CHRl)k-[5 or 6 membered heteroaryl], wherein Rl is hydrogen or methyl and k is 0 or 1;
wherein each of R25, R25a, R26, R27 or R29 or any ring formed when R26 and R27 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1; or
(B) R13 is selected from halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl moiety is optionally substituted by one or more halo or (1-2C)alkoxy, or
R13 is —(CHRo)h—Z13
wherein Ro is hydrogen or methyl;
wherein h is 0 or 1; and
Z13 is —OR25, R25a, —NR25R27, or —C(O)NR26R27;
wherein R25 is (1-4C)alkyl, a carbon-linked 4 to 8-membered heterocyclyl, or —(CHRn)i-[4 to 8-membered heterocyclyl], wherein Rn is hydrogen or methyl and i is 0 or 1;
R25a is (1-4C)alkyl, phenyl, 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRn)i-phenyl, —(CHRn)i-[4 to 8-membered heterocyclyl] or —(CHRn)i-[5 or 6 membered heteroaryl], wherein Rn and i are as defined above;
R26 and R27 are each independently selected from hydrogen, (1-6C)alkyl, a carbon-linked 4 to 8-membered heterocyclyl, or —(CHRm)j-[4 to 8-membered heterocyclyl], wherein Rm is hydrogen or methyl and j is 0 or 1;
or R26 and R27 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
wherein each of R25, R25a, R26, R27 or any ring formed when R26 and R27 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1;
(C) R13 is —(CHRo)h—Z13,
wherein Ro is hydrogen or methyl;
wherein h is 0 or 1; and
Z13 is —OR25, R25a, or —NR26R27;
wherein R25 is (1-4C)alkyl;
R25a is 4 to 8-membered heterocyclyl, a 5 or 6 membered heteroaryl, —(CHRn)i-[4 to 8-membered heterocyclyl] or —(CHRn)i-[5 or 6 membered heteroaryl], wherein Rn is hydrogen and i is 1 or 2;
R26 and R27 are each independently selected from hydrogen or (1-6C)alkyl;
or R26 and R27 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
wherein each of R25, R25a, R26, R27 or any ring formed when R26 and R27 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1;
(D) R13 is —(CHR0)h—Z13,
wherein Ro is hydrogen or methyl;
wherein h is 0 or 1; and
Z13 is —OR25 or —NR26R27;
wherein R25 is (1-4C)alkyl;
R26 and R27 are each independently selected from hydrogen or (1-6C)alkyl;
or R26 and R27 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
wherein each of R25, R26, R27 or any ring formed when R26 and R27 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1;
(E) R13 is —(CHR0)h—Z13,
wherein Ro is hydrogen;
wherein h is 0 or 1; and
Z13 is —OR25 or —NR26R27;
wherein R25 is (1-2C)alkyl;
R26 and R27 are each independently selected from hydrogen or (1-2C)alkyl;
wherein each of R25, R26, R27 or any ring formed when R26 and R27 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A compound according to any one of claims 1 to 18, or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
(i) R14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy, or
R14 is —(CHRk)m—Z14,
wherein Rk is hydrogen;
wherein m is 0 or 1; and
Z14 is —OR30, —NR31R32, —C(O)NR31R32 or —NR33C(O)R34;
wherein R30 is (1-4C)alkyl, (3-7C)cycloalkyl, a carbon-linked 4 to 8-membered heterocyclyl, —(CHRj)o-(3-7C)cycloalkyl, or —(CHRj)o-[4 to 8-membered heterocyclyl], wherein Rj is hydrogen or methyl and o is 0 or 1;
R31 and R32 are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkanoyl, (3-7C)cycloalkyl, a carbon-linked 4 to 8-membered heterocyclyl, —(CHRi)p-(3-7C)cycloalkyl, or —(CHRi)p-[4 to 8-membered heterocyclyl], wherein Ri is hydrogen or methyl and p is 0 or 1
or R31 and R32 are linked, such that, together with the nitrogen atom to which they are attached, they form a 4-8 membered heterocyclic ring;
R33 is hydrogen or methyl;
R34 is (1-6C)alkyl, (3-7C)cycloalkyl, a carbon-linked 4 to 8-membered heterocyclyl, —(CHRh)q-(3-7C)cycloalkyl, or —(CHRh)q-[4 to 8-membered heterocyclyl], wherein Rh is hydrogen or methyl and q is 0 or 1;
wherein R30, R31, R32 or R34, or any ring formed when R31 and R32 are linked, is optionally substituted with one or more Ra;
wherein Ra is as defined in claim 1; or
(ii) R14 is selected from cyano, halo, (1-2C)alkyl, (1-2C)alkoxy, wherein any (1-2C)alkyl or (1-2C)alkoxy is optionally substituted by one or more halo or (1-2C)alkoxy.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A compound according to any one of claims 1 to 19, or pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
(i) each Ra is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, (1-4C)alkyl, or a group
wherein:
L1 is absent or (1-2C)alkylene;
X1 is absent or is selected from the group consisting of —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R14)—, —N(R14)—C(O)—, —NR14—, —SO2N(R14)—, or —N(R14)SO2—, where R14 is hydrogen or (1-2C)alkyl;
Q1 is selected from the group consisting of hydrogen, (1-4C)alkyl, or (3-6C)cycloalkyl;
wherein when Q1 is (1-4C)alkyl, or (3-6C)cycloalkyl, Q1 is optionally substituted with one or more Qa, where each Qa is independently selected from the group consisting of hydroxy, cyano, halogen, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, or (1-3C)haloalkoxy;
(ii) each Ra is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, (1-2C)alkyl, or a group
wherein:
L1 is absent or (1-2C)alkylene;
X1 is absent or is selected from the group consisting of —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R14)—, —N(R14)—C(O)—, —NR14—, —SO2N(R14)—, or —N(R14)SO2—, where R14 is hydrogen or (1-2C)alkyl;
Q1 is selected from the group consisting of hydrogen, (1-2C)alkyl, or (3-6C)cycloalkyl;
wherein when Q1 is (1-2C)alkyl, or (3-6C)cycloalkyl, Q1 is optionally substituted with one or more Qa, where each Qa is independently selected from the group consisting of hydroxy, halogen, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy;
(iii) each Ra is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, (1-2C)alkyl, or a group
wherein:
L1 is absent or (1-2C)alkylene;
X1 is absent or is selected from the group consisting of —O—, —C(O)—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R14)—, —N(R14)—C(O)—, or —NR14—, where R14 is hydrogen or (1-2C)alkyl;
Q1 is selected from the group consisting of hydrogen or (1-2C)alkyl; or
wherein when Q1 is (1-2C)alkyl, Q1 is optionally substituted with one or more Qa, where each Qa is independently selected from the group consisting of hydroxy, halogen, or (1-2C)alkoxy;
(iv) each Ra is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, (1-2C)alkyl, or a group
wherein:
L1 is absent;
X1 is absent or is selected from the group consisting of —O—, —C(O)—, —S(O)0-2—, —C(O)—N(R14)—, —N(R14)—C(O)—, or —NR14—, where R14 is hydrogen or (1-2C)alkyl;
Q1 is selected from the group consisting of hydrogen or (1-2C)alkyl;
wherein when Q1 is (1-2C)alkyl, Q1 is optionally substituted with one or more Qa, where each Qa is methoxy;
(v) each Ra is independently selected from the group consisting of oxo, halogen, cyano, hydroxy, (1-2C)alkyl, or a group
wherein:
L1 is absent;
X1 is absent or is selected from the group consisting of —O—, —C(O)— or —NR14— where R14 is hydrogen or (1-2C)alkyl;
Q1 is selected from the group consisting of hydrogen or (1-2C)alkyl;
wherein when Q1 is (1-2C)alkyl, Q1 is optionally substituted with one or more Qa, where each Qa is methoxy; or
(vi) each Ra is independently selected from the group consisting of oxo, or a group
wherein:
L1 is absent;
X1 is absent or is selected from the group consisting of —O—, —C(O)— or —NR14— where R14 is hydrogen or (1-2C)alkyl;
Q1 is selected from the group consisting of hydrogen or (1-2C)alkyl;
wherein when Q1 is (1-2C)alkyl, Q1 is optionally substituted with one or more Qa, where each Qa is methoxy.

### Claim 21

The compound, or pharmaceutically acceptable salts thereof, according to any preceding claim, wherein the compound is selected from any one of the following:
(S)-(2-(Benzyloxy)-6-hydroxy-4-methoxyphenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-6-hydroxy-4-methoxyphenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(4-(Difluoromethyl)-2-hydroxy-6-((3-methoxybenzyl)oxy)phenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((dimethylamino)methyl)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
1-(3-((2-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxybenzoyl)isoindolin-4-yl)amino)azetidin-1-yl)ethan-1-one
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-(oxetan-3-ylamino)isoindolin-2-yl)methanone
(4-(Difluoro methyl)-2-hydroxy-6-(pyridin-2-ylmethoxy) phenyl) (4-(oxetan-3-ylamino) isoindolin-2-yl) methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(8-(oxetan-3-ylamino)-3,4-dihydroisoquinolin-2(1H)-yl) methanone
(S)-(4-(Difluoromethyl)-2-hydroxy-6-((4-methoxybenzyl)oxy)phenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(4-(Difluoro methyl)-2-hydroxy-6-(pyridin-2-ylmethoxy) phenyl) (4-((tetrahydrofuran-3-yl) amino) isoindolin-2-yl) methanone
(S)-(4-(Difluoromethyl)-2-hydroxy-6-(pyridin-2-ylmethoxy)phenyl)(8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(4-(Difluoromethyl)-2-hydroxy-6-((4-methoxybenzyl)oxy)phenyl)(8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-3-((2-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxybenzoyl)isoindolin-4-yl)amino)-1-methylpyrrolidin-2-one
(S)-3-((2-(2-(benzyloxy)-4-(difluoromethyl)-6-hydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)amino)-1-methylpyrrolidin-2-one
(R)-3-((2-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxybenzoyl)isoindolin-4-yl)amino)-1-methylpyrrolidin-2-one
(R)-3-((2-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)amino)-1-methylpyrrolidin-2-one
3-((2-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxybenzoyl) isoindolin-4-yl)amino)dihydrofuran-2(3H)-one
3-((2-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxybenzoyl)-1,2,3,4-tetrahydroisoquinolin-8-yl) amino) dihydrofuran-2(3H)-one
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-methoxy-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(6-((1H-Imidazol-1-yl) methyl)-4-((tetrahydrofuran-3-yl) amino) isoindolin-2-yl) (2-(benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-methoxy-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-((dimethylamino)methyl)-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(6-((1H-Imidazol-1-yl)methyl)-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)(2-(benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (7-methoxy-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-(1-methyl-1H-imidazol-5-yl)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-(1-methyl-1H-imidazol-4-yl)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-(1-methyl-1H-imidazol-5-yl)-8-((tetrahydrofuran-3-yl) amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-(1-methyl-1H-imidazol-4-yl)-8-((tetrahydrofuran-3-yl) amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-((2-methoxyethyl)amino)isoindolin-2-yl)methanone
2-((2-(2-(Benzyloxy)-4-(difluoro methyl)-6-hydroxybenzoyl) isoindolin-4-yl) amino)-N, N-dimethylacetamide
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (5-((4-methylpiperazin-1-yl) methyl) isoindolin-2-yl) methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-(2-(dimethylamino)ethoxy)isoindolin-2-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((1-methylpiperidin-4-yl)oxy)isoindolin-2-yl)methanone
((2-(benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-((1-methylazetidin-3-yl)amino)isoindolin-2-yl)methanone
(2-(Benzyloxy)-4-(difluoro methyl)-6-hydroxyphenyl) (4-(methylamino) isoindolin-2-yl) methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(8-(methylamino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(8-((2-methoxyethyl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-(2-(dimethylamino)ethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-(2-(dimethylamino)ethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-((dimethylamino)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((dimethylamino)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-((1-methyl piperidin-4-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((1-methyl piperidin-4-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-((4-methyl piperazin-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((4-methyl piperazin-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(7-((1H-Imidazol-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(2-(benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)methanone
(6-((1H-Imidazol-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(2-(benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)methanone
(5-((1H-Imidazol-1-yl)methyl)isoindolin-2-yl)(2-(benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((dimethylamino)methyl)isoindolin-2-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(2-((dimethylamino)methyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(3-((dimethylamino)methyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((1-methylpyrrolidin-3-yl)oxy)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (5-((1-methylpyrrolidin-3-yl)oxy)isoindolin-2-yl)methanone
2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (5-((1-methylazetidin-3-yl)oxy)isoindolin-2-yl) methanone
(4-(Difluoromethyl)-2-hydroxy-6-(pyridin-2-ylmethoxy)phenyl)(5-((1-methylpiperidin-4-yl)oxy)isoindolin-2-yl)methanone
(2-(Cyclopropylmethoxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((1-methylpiperidin-4-yl)oxy)isoindolin-2-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-(pyridin-4-yloxy)isoindolin-2-yl)methanone
(2-(Cyclopropylmethoxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((1-methylpiperidin-4-yl)oxy)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-((1-methyl piperidin-4-yl)oxy)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((1-methylpiperidin-4-yl)oxy)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (6-((1-methylpyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H) yl)methanone
(R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((1-methylpyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H) yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((1-methylazetidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-((1-methylpyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (7-((1-methylpyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-((1-methylazetidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoro methyl)-6-hydroxyphenyl) (5-(2-morpholinoethoxy) isoindolin-2-yl) methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (5-(2-(4-methyl piperazin-1-yl) ethoxy) isoindolin-2-yl) methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(8-(cyclopentylamino)-6-(2-(dimethylamino)ethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-8-(methylamino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(8-(difluoromethyl)-6-(2-(dimethylamino)ethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
((S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-(2-methoxyethoxy)isoindolin-2-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((tetrahydro-2H-pyran-4-yl)oxy)isoindolin-2-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-((tetrahydrofuran-3-yl)oxy)isoindolin-2-yl)methanone
2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl) (8-((tetrahydrofuran-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-(Benzyloxy)-4-fluoro-6-hydroxyphenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-4-fluoro-6-hydroxyphenyl) (4-((tetrahydrofuran-3-yl)amino) isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl) (4-((tetrahydrofuran-3-yl)amino) isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl)(4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl) (6-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(R)-(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl) (6-methoxy-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
(S)-(2-(benzyloxy)-4-chloro-6-hydroxyphenyl)(6-methoxy-4-((tetrahydrofuran-3-yl)amino)isoindolin-2-yl)methanone
3-(Benzyloxy)-5-hydroxy-4-(4-((1-methyl-5-oxopyrrolidin-3-yl)amino)isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(4-(pyrimidin-5-ylamino)isoindoline-2-carbonyl)benzonitrile
(R)-4-(4-((1-Acetylpyrrolidin-3-yl)amino)isoindoline-2-carbonyl)-3-(benzyloxy)-5-hydroxybenzonitrile
(S)-4-(4-((1-Acetylpyrrolidin-3-yl)amino)isoindoline-2-carbonyl)-3-(benzyloxy)-5-hydroxybenzonitrile
(R)-3-(Benzyloxy)-5-hydroxy-4-(4-((1-methyl-5-oxopyrrolidin-3-yl)amino)isoindoline-2-carbonyl)benzonitrile or (S)-3-(benzyloxy)-5-hydroxy-4-(4-((1-methyl-5-oxopyrrolidin-3-yl)amino)isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(4-((oxazol-4-ylmethyl)amino)isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(4-(((tetrahydrofuran-3-yl)methyl)amino) isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(4-methoxyisoindoline-2-carbonyl) benzonitrile
(R)-3-(Benzyloxy)-5-hydroxy-4-(8-((tetrahydrofuran-3-yl)amino)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzonitrile
(R)-3-(benzyloxy)-5-hydroxy-4-(6-methoxy-4-((tetrahydrofuran-3-yl)amino)isoindoline-2-carbonyl)benzonitrile
(S)-3-(Benzyloxy)-5-hydroxy-4-(6-methoxy-4-((tetrahydrofuran-3-yl)amino) isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-4-(5-((dimethylamino)methyl)isoindoline-2-carbonyl)-5-hydroxybenzonitrile
4-(4-((1-Acetylpiperidin-4-yl)amino)isoindoline-2-carbonyl)-3-(benzyloxy)-5-hydroxybenzonitrile
(R)-4-(4-((1-Acetylpiperidin-3-yl)amino)isoindoline-2-carbonyl)-3-(benzyloxy)-5-hydroxybenzonitrile
(S)-4-(4-((1-Acetylpiperidin-3-yl)amino) isoindoline-2-carbonyl)-3-(benzyloxy)-5-hydroxybenzonitrile
3-(Benzyloxy)-5-hydroxy-4-(4-((5-oxotetrahydrofuran-3-yl)amino) isoindoline-2-carbonyl)benzonitrile
(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl) (4-((1-methylazetidin-3-yl)amino)isoindolin-2-yl) methanone
2-(Benzyloxy)-4-chloro-6-hydroxyphenyl) (2-((dimethylamino)methyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)methanone
(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl) (6-(2-(dimethylamino)ethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
1-(3-((2-(2-(Benzyloxy)-4-fluoro-6-hydroxybenzoyl) isoindolin-4-yl)amino)azetidin-1-yl)ethan-1-one
(2-(Benzyloxy)-4-fluoro-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-fluoro-6-hydroxyphenyl) (5-((1-methylpiperidin-4-yl) oxy) isoindolin-2-yl) methadone
3-(Benzyloxy)-5-hydroxy-4-(4-(oxetan-3-ylamino)isoindoline-2-carbonyl)benzonitrile
(S)-3-(Benzyloxy)-5-hydroxy-4-(4-((1-methyl-2-oxopyrrolidin-3-yl)amino)isoindoline-2-carbonyl)benzonitrile
(R)-3-(benzyloxy)-5-hydroxy-4-(4-((1-methyl-2-oxopyrrolidin-3-yl)amino) isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-4-(6-(2-(dimethyl amino) ethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-5-hydroxybenzonitrile
(R)-3-(Benzyloxy)-5-hydroxy-4-(5-((1-methylpyrrolidin-3-yl)oxy)isoindoline-2-carbonyl)benzonitrile
(S)-3-(Benzyloxy)-5-hydroxy-4-(5-((1-methylpyrrolidin-3-yl)oxy)isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(5-((1-methylazetidin-3-yl)oxy)isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(5-((1-methyl piperidin-4-yl)oxy)isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(5-((4-methyl piperazin-1-yl)methyl)isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(5-(2-methoxyethoxy) isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(5-((tetrahydro-2H-pyran-4-yl)oxy) isoindoline-2-carbonyl)benzonitrile
3-Hydroxy-4-(5-((1-methylazetidin-3-yl)oxy)isoindoline-2-carbonyl)-5-(pyridin-2-ylmethoxy)benzonitrile
3-Hydroxy-4-(4-(oxetan-3-ylamino) isoindoline-2-carbonyl)-5-(pyridin-2-ylmethoxy)benzonitrile
(S)-3-Hydroxy-5-(pyridin-2-ylmethoxy)-4-(4-((tetrahydrofuran-3-yl)amino) isoindoline-2-carbonyl)benzonitrile
(S)-3-(Benzyloxy)-5-hydroxy-4-(4-((tetrahydrofuran-3-yl)amino) isoindoline-2-carbonyl)benzonitrile
(S)-3-Hydroxy-5-methoxy-4-(4-((tetrahydrofuran-3-yl)amino)isoindoline-2-carbonyl)benzonitrile
(S)-3-(Cyclopropylmethoxy)-5-hydroxy-4-(4-((tetrahydrofuran-3-yl)amino)isoindoline-2-carbonyl)benzonitrile
(R)-3-(Benzyloxy)-5-hydroxy-4-(4-((tetrahydrofuran-3-yl)amino) isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(isoindoline-2-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(5-methoxyisoindoline-2-carbonyl)benzonitrile
(R)-3-(Benzyloxy)-4-(6-(2-(dimethylamino)ethoxy)-8-((tetrahydrofuran-3-yl)amino)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-5-hydroxybenzonitrile
(S)-3-(Benzyloxy)-4-(6-(2-(dimethylamino)ethoxy)-8-((tetrahydrofuran-3-yl)amino)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-5-hydroxybenzonitrile
4-(4-((1-Acetylazetidin-3-yl)amino)isoindoline-2-carbonyl)-3-(benzyloxy)-5-hydroxybenzonitrile
(S)-3-(Benzyloxy)-5-hydroxy-4-(8-((tetrahydrofuran-3-yl)amino)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzonitrile
(R)-3-(Benzyloxy)-4-(6-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino) isoindoline-2-carbonyl)-5-hydroxybenzonitrile
(S)-3-(Benzyloxy)-4-(6-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino)isoindoline-2-carbonyl)-5-hydroxybenzonitrile
(R)-(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl) (6-(2-(dimethylamino)ethoxy)-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-(Benzyloxy)-4-chloro-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-(Benzyloxy)-6-hydroxy-4-(trifluoromethyl) phenyl) (4-((tetrahydrofuran-3-yl) amino) isoindolin-2-yl) methanone
(S)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-(2-(dimethylamino)ethoxy)-8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-(piperidin-4-yloxy)isoindolin-2-yl)methanone
3-(Benzyloxy)-4-(6-((dimethylamino)methyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carbonyl)-5-hydroxybenzonitrile
3-(Benzyloxy)-5-hydroxy-4-(6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carbonyl)benzonitrile
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((tetrahydrofuran-3-yl)amino)indolin-1-yl)methanone
(S or R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((tetrahydrofuran-3-yl)amino)indolin-1-yl)methanone
3-(Benzyloxy)-5-hydroxy-4-(6-((tetrahydrofuran-3-yl)amino)indoline-1-carbonyl)benzonitrile
3-(Benzyloxy)-5-hydroxy-4-(5-((tetrahydrofuran-3-yl)amino)indoline-1-carbonyl)benzonitrile
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((tetrahydrofuran-3-yl)amino)indolin-1-yl)methanone
(S or R)-(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(5-((tetrahydrofuran-3-yl)amino)indolin-1-yl)methanone
3-(Benzyloxy)-5-hydroxy-4-(7-((1-methyl piperidin-4-yl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-3-carbonyl)benzonitrile hydroformate
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(7-((1-methyl piperidin-4-yl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)methanone
3-(Benzyloxy)-5-hydroxy-4-(6-morpholino-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carbonyl)benzonitrile
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-morpholino-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)methanone
4-(6-Amino-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carbonyl)-3-(benzyloxy)-5-hydroxybenzonitrile hydroformate
(6-Amino-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)(2-(benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)methanone hydroformate
3-(Benzyloxy)-4-(4-(2-(dimethylamino)ethoxy)indoline-1-carbonyl)-5-hydroxybenzonitrile
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-(2-(dimethylamino)ethoxy)indolin-1-yl)methanone
3-(Benzyloxy)-4-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carbonyl)-5-hydroxybenzonitrile
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl)methanone
3-(Benzyloxy)-4-(2-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-6-carbonyl)-5-hydroxybenzonitrile
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(2-(2-(dimethylamino)ethoxy)-4-((tetrahydrofuran-3-yl)amino)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone
3-(Benzyloxy)-5-hydroxy-4-(6-((tetrahydrofuran-3-yl)amino)-1,2,3,4-tetrahydroquinoline-1-carbonyl)benzonitrile
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(6-((tetrahydrofuran-3-yl)amino)-3,4-dihydroquinolin-1(2H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-((tetrahydrofuran-3-yl)amino)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-1-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-1-yl)methanone
(2-(Benzyloxy)-4-(difluoromethyl)-6-hydroxyphenyl)(4-((tetrahydrofuran-3-yl)amino)indolin-1-yl)methanone
(S)-(4-(Difluoromethyl)-2-hydroxy-6-((1-methyl-1H-indazol-6-yl)methoxy)phenyl)(8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-((2-Oxabicyclo[2.1.1]hexan-1-yl)methoxy)-4-(difluoromethyl)-6-hydroxyphenyl) (8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(4-(Difluoromethyl)-2-hydroxy-6-(isoquinolin-6-ylmethoxy)phenyl)(8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(4-(Difluoromethyl)-2-hydroxy-6-(isoquinolin-7-ylmethoxy)phenyl)(8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
(S)-(2-((1H-Benzo[d]imidazol-2-yl)methoxy)-4-(difluoromethyl)-6-hydroxyphenyl)(8-((tetrahydrofuran-3-yl)amino)-3,4-dihydroisoquinolin-2(1H)-yl)methanone.

### Claim 22

A pharmaceutical composition comprising a compound as defined in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A compound, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-21, or a pharmaceutical composition as defined in claim 22:
(i) for use in therapy;
(ii) the treatment of cancer;
(iii) the treatment of cancer, wherein the compound or pharmaceutical composition is administered in combination with another anticancer agent (e.g. a chemotherapeutic agent, an immune checkpoint inhibitor, an immune stimulator or DNA damage repair modulator);
(iv) the treatment of a triplet repeat disorder.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method of treating cancer or a triplet repeat disorder in a patient in need of such treatment, the method involving administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-21, or a pharmaceutical composition as defined in claim 22.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24)

A method of treating cancer according to claim 24, wherein the method comprises administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-21, or a pharmaceutical composition as defined in claim 22, in combination with another anticancer agent (e.g. a chemotherapeutic agent, an immune checkpoint inhibitor, an immune stimulator or DNA damage repair modulator).
